| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.39 |
| PRIMECAP Management Co. | 11.06 |
| PRIMECAP Management Co. | 10.88 |
| Vanguard Group, Inc. (Subfiler) | 8.00 |
| The Vanguard Group, Inc. | 7.97 |
| Vanguard PRIMECAP Fund | 6.23 |
| State Street Corp. | 4.74 |
| Wellington Management Co. LLP | 3.71 |
| BlackRock Fund Advisors | 3.43 |
| T. Rowe Price Investment Management, Inc. | 3.28 |
| Vanguard Health Care Fund | 3.15 |
| Vanguard Total Stock Market ETF | 3.13 |
| Vanguard 500 Index Fund | 2.42 |
| JPMorgan Investment Management, Inc. | 2.41 |
| Geode Capital Management LLC | 2.24 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7'800 | 7'400 | 9'100 | 9'610 | 8'725 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1.55 | 1.72 | 1.36 | 1.08 | 1.08 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7'641 | 8'382 | 6'887 | 7'857 | 9'791 |
| Summe Anlagevermögen | 18'976 | 19'784 | 18'612 | 18'589 | 20'109 |
| Summe Aktiva | 25'289 | 27'234 | 24'619 | 23'877 | 24'554 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 5'937 | 6'441 | 7'911 | 7'693 | 6'711 |
| Summe Fremdkapital | 12'257 | 13'895 | 13'933 | 12'918 | 11'166 |
| Summe Eigenkapital | 13'032 | 13'339 | 10'686 | 10'960 | 13'388 |
| Summe Passiva | 25'289 | 27'234 | 24'619 | 23'877 | 24'554 |
Adresse
| 225 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 679-2000 |
| URL | http://www.biogen.com |
Management
|
Adam Keeney
Executive VP & Head-Corporate Development |
|
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences |
|
Ann E. Beasley
Chief Compliance Officer & Senior Vice President |
|
Caroline D. Dorsa
Chairman |
|
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
|
Chuck Triano
Senior Vice President |
|
Eric K. Rowinsky
Independent Director |
|
Ginger Gregory
Chief Human Resources Officer & Executive VP |
|
Jake Elkins
Vice President & Head-Acute Neurology Research |
|
Jane Grogan
Executive Vice President & Head-Research |
|
Jesus B. Mantas
Independent Director |
|
Mahalakshmi Radhakrishnan
Chief Medical Officer & Group Senior VP |
|
Maria C. Freire
Independent Director |
|
Michael E. Dambach
Treasurer & Vice President |
|
Michael Hencke
Executive Director-Investor Relations |
|
Michael R. McDonnell
Chief Financial Officer & Executive Vice President |
|
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
|
Priya Singhal
Executive Vice President & Head-Development |
|
Rachid Izzar
Executive Vice President |
|
Robert Kilo
Account Director |
|
Robin C. Kramer
Chief Accounting Officer & Senior Vice President |
|
Rohin Mhatre
Senior VP-Product & Technology Development |
|
Stephen A. Sherwin
Independent Director |
|
Susan H. Alexander
Secretary, Chief Legal Officer & Executive VP |
|
Susan Langer
Independent Director |
|
Wendell C. Taylor
Chief Corporation Counsel & Assistant Secretary |
|
William A. Hawkins
Independent Director |